Cat. No. 3000

Iressa C22H24ClFN4O3 [184475-35-2]

Price and Availability

For Iressa pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Special Conditions

No more than 1 g per individual per year to be sold without prior permission from the license holder.

Alternative Names: Gefitinib, ZD 1839

Chemical Name: N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine

Biological Activity

Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts.

Licensing Information

Sold for research purposes only under agreement from AstraZeneca

Technical Data

Soluble to 100 mM in DMSO and to 10 mM in ethanol
>98 %
Store at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet


Baselga et al (2000) ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 (Suppl. 1) 33. PMID: 11129170.

Ciardiello et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 6 2053. PMID: 10815932.

McKillop et al (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 4 641. PMID: 15827338.

If you know of a relevant citation for this product please let us know.

Keywords: Iressa, supplier, Orally, active, selective, EGFR, inhibitors, Epidermal, Growth, Factors, Receptors, ErbB, Her, Receptor, Tyrosine, Kinases, RTKs, AstraZeneca, ZD1839

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Guide

Highlights over 350 products for cancer research. view PDF today.

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 400 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

New Product Guide


Highlights 130 new products added in the first half of 2015. View PDF today.

divider line

New Products in this Area

PF 06463922

High affinity and selective ALK and ROS1 inhibitor


Insulin degrading enzyme (IDE) inhibitor


Potent c-MET/ALK inhibitor

AC 710

Potent and selective PDGFR family inhibitor

SPP 86

Potent RET inhibitor

SGX 523

Selective and potent c-MET kinase inhibitor

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Pharmacology 2015

Pharmacology 2015

December 15 - 17, 2015

London UK